Subscribe

New Migraine Screening Tool Shows Promise

VBCN - April 2016 Volume 3, No 1 - Migraine
Laura Morgan

Migraine is the third most common medical condition and the eighth leading cause of disability worldwide, according to the World Health Organization; yet, migraines are still underdiagnosed and undertreated. The misdiagnosis of migraines is partly to blame for patients not receiving optimal care.

The US Headache Consortium recommends developing and validating cost-efficient screening tools. Identifying symptoms specific to migraines has been one of the bigger hurdles for developing migraine screening tools; in fact, nausea has largely been the only symptom used in studies to discriminate migraines from other headaches.

A. Brooke Walters, PhD, and Todd A. Smitherman, PhD, MS, of the Department of Psychology, University of Mississippi, Oxford, have developed and validated a new, 4-item migraine screening algorithm to help clinicians differentiate migraine headaches from nonmigraine headaches (Walters AB, Smitherman TA. Headache. 2016;56:86-94).

Study Details

A total of 1829 young adults at a southeastern university completed a computer-administered Structured Diagnostic Interview for Headache. Based on their answers, participants were divided into 2 groups—the migraine group, comprised of those who met the 2013 International Classification of Headache Disorders, Third Edition (ICHD-3) criteria for episodic or chronic migraine, and the nonmigraine group, which included participants with headaches other than migraines.

The Structured Diagnostic Interview for Headache was slightly modified to align with the ICHD-3 criteria, and included questions related to ICHD-3 symptoms of migraines, headache frequency, disability, and other primary and secondary headache disorders.

Headache duration of 4 to 72 hours showed the highest sensitivity, followed by severity ≥5, photophobia, and phonophobia. Conversely, vomiting showed the highest specificity, followed by headache, duration of 4 to 72 hours, nausea, and headache-related disability.

Based on its specificity, sensitivity, and optimal operating point, the final migraine assessment model is called Migraine-4 and comprises 4 variables:

  1. Headache duration of 4 to 72 hours
  2. Nausea
  3. Photophobia
  4. Phonophobia.

This study is not the first to identify that nausea, phonophobia, and photophobia are the most effective symptoms for distinguishing migraines from other headaches. It is, however, the first study to develop a migraine model that includes these 4 variables, and to validate this as a functional migraine screening tool.

The Migraine-4 Screening Tool

Unlike previous studies that showed that disability was predictive of migraines, no such correlation was evident in this study; the investigators attributed this discrepancy to the variability in the way disability was defined in the different studies, ultimately concluding that the utility of this variable cannot be compared.

Conversely, the duration of headache was found to be an important diagnostic parameter of migraines in this study but not in other studies, possibly because this study did not categorize participants with probable migraines in the migraine group whereas other studies did. Individuals with probable migraines experience migraine attacks <4 hours in duration. In addition, the duration of headache is often not included in these types of studies as a potential diagnostic parameter, even though it is an impor­tant variable in the ICHD-3.

Overall, Migraine-4 has higher sensitivity and specificity values than other migraine screening tools, including ID Migraine and the Migraine Screen Questionnaire. The investigators underlined, however, that Migraine-4 is a screening tool only and should not be used alone to diagnose migraines.

“Because physicians often do not have time to assess all diagnostic criteria or conduct a lengthy structured interview, inclusion of this four-item measure in clinical settings could be used to identify migraineurs that so often go undiagnosed, so long as it performs well in future studies with clinical samples,” the researchers concluded.

Related Items
Alemtuzumab Reduces Disability in Patients with Active Relapsing-Remitting Multiple Sclerosis
Laura Morgan
VBCN - November 2016 Volume 3, No 3 published on November 22, 2016 in Multiple Sclerosis
Reducing the Cost and Improving the Care of Patients with Multiple Sclerosis
Laura Morgan
VBCN - November 2016 Volume 3, No 3 published on November 22, 2016 in Multiple Sclerosis
Stem-Cell Therapy Reverses Disability in Multiple Sclerosis
Laura Morgan
VBCN - November 2016 Volume 3, No 3 published on November 22, 2016 in Multiple Sclerosis
Lifestyle Enrichment May Have Some Effect on Alzheimer's Disease Biomarkers
Laura Morgan
VBCN - July 2016 Volume 3, No 2 published on July 25, 2016 in Alzheimer’s Disease/Dementia
Osimertinib Effective for First-Line Treatment of EGFR Mutation–Positive NSCLC
Laura Morgan
VBCC - June 2016, Vol 7, No 5 published on June 17, 2016 in Lung Cancer
BDNF Gene Expression Slows Cognitive Decline in Alzheimer’s Disease
Laura Morgan
VBCN - April 2016 Volume 3, No 1 published on May 3, 2016 in Alzheimer’s Disease/Dementia
Aptiom Improves Quality of Life and Depression in Patients with Partial-Onset Seizures
Laura Morgan
VBCN - April 2016 Volume 3, No 1 published on May 3, 2016 in Epilepsy Update
Medical Costs, Lost Productivity Are Substantial for Chronic Migraine
Wayne Kuznar
VBCN - April 2016 Volume 3, No 1 published on May 3, 2016 in Migraine
American Cancer Society Updates Breast Cancer Screening Guidelines for Women at Average Risk
Laura Morgan
VBCC - December 2015, Vol 6, No 11 published on December 16, 2015 in Clinical Guidelines
Medical and Psychosocial Impact of Oral Therapy on Patients with Metastatic Castration-Resistant Prostate Cancer
Laura Morgan
VBCC - September 2015, Vol 6, No 8 published on September 17, 2015 in Prostate Cancer
Last modified: May 12, 2016
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology